(lp0
S"Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies ... Motley Fool - Mar 14, 2017 It's been an up-and-down ride for Celldex Therapeutics  shareholders since the biotech reported the late-stage failure for Rintega.Celldex Therapeutics, Inc.  Shares Bought by Fmr LLC - Chaffey BreezeAnalyst Activity  Jefferies Group LLC Lowers Its Price Target On Celldex ... - Market Exclusive"
p1
aS"Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why Motley Fool - Mar 7, 2017 Shares of Celldex Therapeutics, Inc.  a clinical-stage biotech developing targeted cancer therapies, were down about 10% as of 2:45 p.m.Celldex Therapeutics  Q4 Earnings: What's in Store? - Yahoo Finance"
p2
aS'Better Buy: Agenus Inc. vs. Celldex Therapeutics Motley Fool - Mar 10, 2017 Agenus Inc  and Celldex Therapeutics, Inc.  bear an uncanny resemblance to each other. Both clinical-stage biotechs are focused on developing novel cancer therapies and reported clinical-trial failures with vaccine&nbsp;...Stocks That Should Be on Your Watchlist- Celldex Therapeutics, Inc. '
p3
aS'Why You Should  Buy Celldex Therapeutics, Inc. Motley Fool - Dec 6, 2016 Global spending on cancer medicines is rising along with average life spans, from $107 billion last year to an estimated $150 billion by 2020.Is Celldex Therapeutics  Stock a Solid Choice Right Now? - Nasdaq'
p4
aS"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Inc Motley Fool - Feb 28, 2017 Celldex Therapeutics, Inc.  and Juno Therapeutics Inc  are two of last year's worst-performing biotech stocks.Celldex Therapeutics Inc.  Soars 9.82% on February 27 - Equities.comShares of Celldex Therapeutics, Inc.  Plunge -6.59% - Energy Index"
p5
aS"Celldex Therapeutics, Inc.'s Biggest Failure in 2016 Motley Fool - Dec 15, 2016 It hasn't been a particularly good year for Celldex Therapeutics , with shares down over 75% year to date."
p6
aS"Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 Motley Fool - Jan 5, 2017 Although a surprising trial failure made 2016 a punishing year for Celldex Therapeutics  investors, the beaten-up biotech took several wise steps that could set it up for success in 2017 and beyond."
p7
aS'Buy, Sell or Hold? Analysts Approach: Celldex Therapeutics, Inc. , Ares ... The USA Commerce - Mar 17, 2017 Celldex Therapeutics, Inc.  share price increased in the last trading session with a previous 52-week high of $5.13.'
p8
aS'Celldex Therapeutics, Inc.  Valuation in Focus Business Review - Mar 17, 2017 Celldex Therapeutics, Inc.  has an ERP5 rank of 13914. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies.'
p9
aS'Hot Stock for Investors: Celldex Therapeutics, Inc.  FactsReporter - Mar 17, 2017 Celldex Therapeutics, Inc. on 03/14/2017 reported its EPS as $-0.3 with the analysts projecting the EPS of the stock as $-0.34.'
p10
a.